Canada · Delayed Price · Currency is CAD ATS Corporation Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and adjusted earnings grew 11% year-over-year, with Q4 margins and cash flow improving. Fiscal 2027 guidance calls for modest revenue growth and 50-75 bps margin expansion, supported by a CAD 2B backlog and strong life sciences and energy segments.
-
The incoming CEO outlined a strategy focused on margin expansion, disciplined M&A, and leveraging strengths in life sciences and nuclear markets. Operational improvements, portfolio diversification, and targeted investments in high-margin and service-oriented businesses are key priorities.
-
Q3 revenue rose 16.7% year-over-year to $761M, with strong growth in life sciences and energy. Order backlog remains robust at $2.1B, and margin expansion is a key focus. Capital allocation will prioritize M&A and innovation as leverage returns to target range.
-
Q2 saw 19% revenue growth year-over-year, strong margins, and a record order backlog of CAD 2.1 billion. Guidance for high single-digit revenue growth and margin expansion in fiscal 2026 is reaffirmed, with robust performance across life sciences, energy, and food segments.
-
Q1 revenue grew 6% year-over-year to $737 million, with strong contributions from acquisitions and a robust $2.1 billion order backlog. Margins improved sequentially, and the outlook for revenue and margin expansion remains positive, supported by healthy demand in life sciences, energy, and food sectors.
Fiscal Year 2025
-
Interim leadership is guiding the company through a period of strong revenue growth, margin expansion, and strategic investments in high-growth sectors like Life Sciences and nuclear. The CEO search is well advanced, and operational continuity is maintained through a decentralized structure.
-
Automation demand is rising due to supply chain derisking and labor shortages, with strong growth in life sciences, nuclear, and food sectors. Recurring revenue and margin expansion remain key focuses, supported by innovation, M&A, and a robust backlog.
-
The meeting highlighted leadership transitions, strong performance in diversified markets, and strategic acquisitions. All director nominees and resolutions were approved, with over 90% shareholder participation and no questions raised during the Q&A.
-
Record annual order bookings and a strong backlog position the company for growth in fiscal 2026, despite lower revenues and earnings in 2025 due to EV market headwinds. The EV settlement improved financial flexibility, and margin expansion is expected as transportation recovers.
-
Strong bookings and a healthy backlog support high single-digit to low double-digit growth targets, with a focus on life sciences, automation, and services. Margin expansion is driven by supply chain, standardization, and services, while capital allocation emphasizes internal investment and strategic M&A.
-
Strong bookings in life sciences, especially GLP-1 and radiopharma, are driving growth, supported by disciplined M&A and robust supply chain management. The EV segment is managed as a harvest strategy, while nuclear energy bookings are rising, particularly in CANDU refurbishment.
-
Revenue has tripled in eight years, driven by Life Sciences, services, and digital expansion. The business is diversifying across regulated, high-value markets, leveraging innovation, global reach, and M&A. Recurring revenue and margin growth are supported by services and digital solutions.
-
Third quarter bookings surged 32% year-over-year, with record backlogs in Life Sciences and food and beverage. Revenue declined 13% due to lower EV sales, but margin expansion and strong order pipelines support a positive outlook into fiscal 2026.
-
Q2 saw strong life sciences growth and record backlog, offsetting transportation headwinds and lower revenues. Strategic acquisitions and cost realignment support future margin improvement, while a major EV customer dispute and elevated leverage remain key risks.
-
Order bookings rose 18% year-over-year, led by life sciences, while Q1 revenue declined 8% due to transportation softness. Backlog remains strong at CAD 1.9 billion, with cost realignment actions underway and acquisitions expanding offerings.
Fiscal Year 2024
-
Business is focused on high-value automation for life sciences and food safety, with strong organic and M&A-driven growth. Life sciences, especially auto-injectors and radiopharma, are key drivers, while margin expansion is targeted through supply chain and operational improvements.
-
Life sciences and regulated food drive strong organic growth, while transportation is de-emphasized after cost restructuring. Margin expansion is targeted through supply chain, standardization, and recurring revenue, with capital allocated to innovation and M&A.
-
A decentralized solutions provider, the business has grown through innovation, acquisitions, and a focus on regulated markets like life sciences and energy. Revenue is driven by equipment, software, and ongoing services, with digital and recurring streams expanding. GLP-1 and auto-injector markets are expected to fuel growth for at least five more years.
-
Record revenues and earnings were achieved in fiscal 2024, supported by strong organic growth and strategic acquisitions. All director nominees and resolutions passed, with continued focus on ESG, innovation, and expansion in regulated markets.
-
A global automation provider emphasized its strategic shift to regulated, high-quality markets, robust M&A-driven growth, and technology innovation, including AI and software. Long-term prospects remain strong in life sciences, food, and EV, with disciplined capital allocation and a focus on value-added solutions.
-
Revenue has tripled in seven years, driven by a shift to regulated, high-value markets and strong M&A activity. Proprietary technology, AI integration, and expanded services have boosted margins and customer impact. Life sciences and EV remain key growth areas, with disciplined capital allocation supporting ongoing improvement.